What is the principle of antibiotic stewardship when transitioning from IV to oral therapy?

• A. Stay on IV until culture shows susceptibility.
• B. Step down to the narrowest effective spectrum and switch to an appropriate oral regimen as soon as feasible.
• C. Switch to broad-spectrum oral regimen when possible.
• D. Stop antibiotics when switching route.

Answer: (B)

The main idea is to de-escalate and switch to the simplest effective therapy in an oral form as soon as it’s safe. This is a core principle of antibiotic stewardship: when you have a reliable organism or clinical improvement, you don’t keep a patient on broad, IV therapy longer than needed. Instead, you move to the narrowest antibiotic that will adequately treat the infection and switch to an oral regimen that is appropriate and has good bioavailability.

This approach reduces exposure to unnecessary broad-spectrum agents, lowers risks tied to IV lines (infections, thrombophlebitis), shortens hospital stays, lowers costs, and helps limit resistance and adverse effects. The switch is made when the patient is clinically stable, can tolerate oral intake, and the oral drug chosen is capable of effectively treating the pathogen (often guided by culture results showing susceptibility).

Why the other options aren’t aligned with stewardship: staying on IV until culture results are known can delay de-escalation and prolong IV-related risks; switching to a broad-spectrum oral regimen contradicts the goal of narrowing therapy; stopping antibiotics entirely at the moment of route change risks undertreatment if the infection is still present.